UAE Atopic Dermatitis Drugs Market Size & Outlook
UAE atopic dermatitis drugs market, 2018-2030 (US$M)
Related Markets
UAE atopic dermatitis drugs market highlights
- The UAE atopic dermatitis drugs market generated a revenue of USD 69.7 million in 2024 and is expected to reach USD 120.4 million by 2030.
- The UAE market is expected to grow at a CAGR of 9.4% from 2025 to 2030.
- In terms of segment, biologics was the largest revenue generating drug class in 2024.
- PDE4 Inhibitors is the most lucrative drug class segment registering the fastest growth during the forecast period.
Atopic dermatitis drugs market data book summary
| Market revenue in 2024 | USD 69.7 million |
| Market revenue in 2030 | USD 120.4 million |
| Growth rate | 9.4% (CAGR from 2025 to 2030) |
| Largest segment | Biologics |
| Fastest growing segment | PDE4 Inhibitors |
| Historical data | 2018 - 2023 |
| Base year | 2024 |
| Forecast period | 2025 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Corticosteroids, Calcineurin Inhibitors, PDE4 Inhibitors, Biologics |
| Key market players worldwide | Pfizer Inc, Sanofi SA, AbbVie Inc, Galderma Group AG Registered Shares, Eli Lilly and Co, Regeneron Pharmaceuticals Inc, Otsuka Holdings Co Ltd, Novartis AG ADR, Incyte Corp, LEO Pharma |
Other key industry trends
- In terms of revenue, UAE accounted for 0.4% of the global atopic dermatitis drugs market in 2024.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Middle East & Africa, Saudi Arabia atopic dermatitis drugs market is projected to lead the regional market in terms of revenue in 2030.
- South Africa is the fastest growing regional market in Middle East & Africa and is projected to reach USD 109.3 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Atopic Dermatitis Drugs Market Scope
Atopic Dermatitis Drugs Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
UAE atopic dermatitis drugs market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to atopic dermatitis drugs market will help companies and investors design strategic landscapes.
Biologics was the largest segment with a revenue share of 45.05% in 2024. Horizon Databook has segmented the UAE atopic dermatitis drugs market based on corticosteroids, calcineurin inhibitors, pde4 inhibitors, biologics covering the revenue growth of each sub-segment from 2018 to 2030.
Increasing incidence of atopic dermatitis is one of the major factors driving the market in the UAE. The variation in prevalence of atopic dermatitis ranges between 7.5% and 22.5%. Other factors, such as genetics, also play a crucial role in the high prevalence of atopic dermatitis in the UAE.
For instance, gene polymorphism and consanguineous marriage rates are high in the country, which can increase the likelihood of the disease. As per CIA World Factbook’s observations, the prevalence of adult obesity in the UAE was 31.70%, and the country ranks 20th in the world.
Diabetes increases the chances of acquiring the disease. In March 2018, the UAE became one of the five countries to adopt and approve Dupilumab by Sanofi, demonstrating the active regulatory bodies that are open to change and making efforts for adoption of novel treatments.
Reasons to subscribe to UAE atopic dermatitis drugs market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of UAE atopic dermatitis drugs market databook
-
Our clientele includes a mix of atopic dermatitis drugs market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the UAE atopic dermatitis drugs market , including forecasts for subscribers. This country databook contains high-level insights into UAE atopic dermatitis drugs market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
UAE atopic dermatitis drugs market size, by drug class, 2018-2030 (US$M)
UAE Atopic Dermatitis Drugs Market Outlook Share, 2024 & 2030 (US$M)
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
